FDA Declines Rush Request for Alzheimer’s Drug Donanemab
The FDA rejected Eli Lilly’s request to expedite the approval process for experimental Alzheimer’s drug donanemab, but the drug’s Phase 3 trial is carrying…
The FDA rejected Eli Lilly’s request to expedite the approval process for experimental Alzheimer’s drug donanemab, but the drug’s Phase 3 trial is carrying…
To engage and include relatives living with early Alzheimer’s or dementia in family time, get them talking about their favorite memories from the past….
Alzheimer’s and dementia experts tackle reader questions on Alzheimer’s sundowning symptoms. What stage of Alzheimer’s is sundowning? What are the early signs, how long…
A second patient has died of brain bleeds — an anti-amyloid side effect — during the clinical trial extension of Eisai’s Alzheimer’s treatment lecanemab….
This Giving Tuesday, consider donating to help fund Alzheimer’s and dementia research. More than 6.5 million Americans are living with Alzheimer’s. By 2050, this…
Why to stop calling them “senior moments” — and how to tell the difference between these typical aging-related memory lapses and dementia. Mild cognitive…
In Phase 3 trials, Roche’s experimental Alzheimer’s drug gantenerumab has failed to meet its objectives for slowing cognitive decline. Most Alzheimer’s treatments on the market…